Table 3.
Outcome measure |
Predicted risk groupNo. (%) |
P | ||
---|---|---|---|---|
Low-risk (n= 48) | High-risk (n= 30) | |||
Resectability Rate | 44 (92) | 16 (53) | <0.001 | |
R0 | 35 (73) | 10 (33) | 0.001 | |
R1 | 9 (19) | 6 (20) | 0.892 | |
Locally-advanced | 0 (0) | 5 (17) | 0.007 | |
Metastatic | 4 (8) | 9 (30) | 0.026 | |
AJCC Stage | 1A | 3 (6) | 0 (0) | 0.002 |
1B | 3 (6) | 2 (6) | ||
2A | 13 (27) | 4 (13) | ||
2B | 25 (52) | 10 (33) | ||
3 | 0 (0) | 5 (17) | ||
4 | 4 (8) | 9 (30) | ||
Median number of total nodes per specimen if resected (range) | 10 (3–34) | 12 (4–41) | 0.30 | |
Median number of positive nodes if Stage 2B (range) | 2 (1–10) | 3 (1–10) | 0.81 | |
Mean node ratio if Stage 2B (±SD) | 0.33 (±0.23) | 0.27 (±0.24) | 0.50 | |
Adjuvant chemotherapya | 32 (78) | 16 (73) | 0.76 | |
Adjuvant radiationb | 9 (23) | 7 (33) | 0.54 | |
Tumour location, head | 38 (79) | 22 (73) | 0.55 |
Data for adjuvant chemotherapy were known for 41 low-risk and 22 high-risk lesions.
Data for adjuvant radiation were known for 39 low-risk and 21 high-risk lesions.